Literature DB >> 18981246

Direct and indirect impairment of human dendritic cell function by virulent Francisella tularensis Schu S4.

Jennifer C Chase1, Jean Celli, Catharine M Bosio.   

Abstract

The gram-negative, facultative intracellular bacterium Francisella tularensis causes acute, lethal pneumonic disease following infection with only 10 CFU. The mechanisms used by the bacterium to accomplish this in humans are unknown. Here, we demonstrate that virulent, type A F. tularensis strain Schu S4 efficiently infects and replicates in human myeloid dendritic cells (DCs). Despite exponential replication over time, Schu S4 failed to stimulate transforming growth factor beta, interleukin-10 (IL-10), IL-6, IL-1beta, IL-12, tumor necrosis factor alpha, alpha interferon (IFN-alpha), and IFN-beta throughout the course of infection. Schu S4 also suppressed the ability of directly infected DCs to respond to different Toll-like receptor agonists. Furthermore, we also observed functional inhibition of uninfected bystander cells. This inhibition was mediated, in part, by a heat-stable bacterial component. Lipopolysaccharide (LPS) from Schu S4 was present in Schu S4-conditioned medium. However, Schu S4 LPS was weakly inflammatory and failed to induce suppression of DCs at concentrations below 10 microg/ml, and depletion of Schu S4 LPS did not significantly alleviate the inhibitory effect of Schu S4-conditioned medium in uninfected human DCs. Together, these data show that type A F. tularensis interferes with the ability of a central cell type of the immune system, DCs, to alert the host of infection both intra- and extracellularly. This suggests that immune dysregulation by F. tularensis operates on a broader and more comprehensive scale than previously appreciated.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18981246      PMCID: PMC2612294          DOI: 10.1128/IAI.00879-08

Source DB:  PubMed          Journal:  Infect Immun        ISSN: 0019-9567            Impact factor:   3.441


  52 in total

1.  Measles virus induces abnormal differentiation of CD40 ligand-activated human dendritic cells.

Authors:  C Servet-Delprat; P O Vidalain; H Bausinger; S Manié; F Le Deist; O Azocar; D Hanau; A Fischer; C Rabourdin-Combe
Journal:  J Immunol       Date:  2000-02-15       Impact factor: 5.422

2.  Inhibition of lipopolysaccharide-induced signal transduction in endotoxin-tolerized mouse macrophages: dysregulation of cytokine, chemokine, and toll-like receptor 2 and 4 gene expression.

Authors:  A E Medvedev; K M Kopydlowski; S N Vogel
Journal:  J Immunol       Date:  2000-06-01       Impact factor: 5.422

Review 3.  Dendritic cells and the control of immunity.

Authors:  J Banchereau; R M Steinman
Journal:  Nature       Date:  1998-03-19       Impact factor: 49.962

4.  Induction of maturation of human blood dendritic cell precursors by measles virus is associated with immunosuppression.

Authors:  J J Schnorr; S Xanthakos; P Keikavoussi; E Kämpgen; V ter Meulen; S Schneider-Schaulies
Journal:  Proc Natl Acad Sci U S A       Date:  1997-05-13       Impact factor: 11.205

5.  Purified lipopolysaccharide from Francisella tularensis live vaccine strain (LVS) induces protective immunity against LVS infection that requires B cells and gamma interferon.

Authors:  V C Dreisbach; S Cowley; K L Elkins
Journal:  Infect Immun       Date:  2000-04       Impact factor: 3.441

6.  Minimal requirements for murine resistance to infection with Francisella tularensis LVS.

Authors:  K L Elkins; T R Rhinehart-Jones; S J Culkin; D Yee; R K Winegar
Journal:  Infect Immun       Date:  1996-08       Impact factor: 3.441

7.  IL-10 released by concomitant TLR2 stimulation blocks the induction of a subset of Th1 cytokines that are specifically induced by TLR4 or TLR3 in human dendritic cells.

Authors:  Fabio Re; Jack L Strominger
Journal:  J Immunol       Date:  2004-12-15       Impact factor: 5.422

8.  Intravenous endotoxin suppresses the cytokine response of peripheral blood mononuclear cells of healthy humans.

Authors:  E V Granowitz; R Porat; J W Mier; S F Orencole; G Kaplanski; E A Lynch; K Ye; E Vannier; S M Wolff; C A Dinarello
Journal:  J Immunol       Date:  1993-08-01       Impact factor: 5.422

9.  Phase variation in Francisella tularensis affecting intracellular growth, lipopolysaccharide antigenicity and nitric oxide production.

Authors:  S C Cowley; S V Myltseva; F E Nano
Journal:  Mol Microbiol       Date:  1996-05       Impact factor: 3.501

10.  Efficient presentation of soluble antigen by cultured human dendritic cells is maintained by granulocyte/macrophage colony-stimulating factor plus interleukin 4 and downregulated by tumor necrosis factor alpha.

Authors:  F Sallusto; A Lanzavecchia
Journal:  J Exp Med       Date:  1994-04-01       Impact factor: 14.307

View more
  57 in total

1.  Proteomic analysis of bronchoalveolar lavage fluid proteins from mice infected with Francisella tularensis ssp. novicida.

Authors:  Susan M Varnum; Bobbie-Jo M Webb-Robertson; Joel G Pounds; Ronald J Moore; Richard D Smith; Charles W Frevert; Shawn J Skerrett; David Wunschel
Journal:  J Proteome Res       Date:  2012-06-22       Impact factor: 4.466

2.  Deletion of ripA alleviates suppression of the inflammasome and MAPK by Francisella tularensis.

Authors:  Max Tze-Han Huang; Brittany L Mortensen; Debra J Taxman; Robin R Craven; Sharon Taft-Benz; Todd M Kijek; James R Fuller; Beckley K Davis; Irving Coy Allen; Willie June Brickey; Denis Gris; Haitao Wen; Thomas H Kawula; Jenny Pan-Yun Ting
Journal:  J Immunol       Date:  2010-10-04       Impact factor: 5.422

3.  Genetic identification of unique immunological responses in mice infected with virulent and attenuated Francisella tularensis.

Authors:  Luke C Kingry; Ryan M Troyer; Nicole L Marlenee; Helle Bielefeldt-Ohmann; Richard A Bowen; Alan R Schenkel; Steven W Dow; Richard A Slayden
Journal:  Microbes Infect       Date:  2010-11-09       Impact factor: 2.700

4.  Detrimental Influence of Alveolar Macrophages on Protective Humoral Immunity during Francisella tularensis SchuS4 Pulmonary Infection.

Authors:  Donald J Steiner; Yoichi Furuya; Dennis W Metzger
Journal:  Infect Immun       Date:  2018-03-22       Impact factor: 3.441

5.  IFN-β mediates suppression of IL-12p40 in human dendritic cells following infection with virulent Francisella tularensis.

Authors:  Timothy J Bauler; Jennifer C Chase; Catharine M Bosio
Journal:  J Immunol       Date:  2011-07-13       Impact factor: 5.422

6.  CpG oligodeoxyribonucleotides protect mice from Burkholderia pseudomallei but not Francisella tularensis Schu S4 aerosols.

Authors:  David A Rozak; Herbert C Gelhaus; Mark Smith; Mojgan Zadeh; Louis Huzella; David Waag; Jeffrey J Adamovicz
Journal:  J Immune Based Ther Vaccines       Date:  2010-02-05

7.  A Francisella tularensis locus required for spermine responsiveness is necessary for virulence.

Authors:  Brian C Russo; Joseph Horzempa; Dawn M O'Dee; Deanna M Schmitt; Matthew J Brown; Paul E Carlson; Ramnik J Xavier; Gerard J Nau
Journal:  Infect Immun       Date:  2011-06-13       Impact factor: 3.441

8.  Francisella tularensis RipA protein topology and identification of functional domains.

Authors:  Brittany L Mortensen; James R Fuller; Sharon Taft-Benz; Edward J Collins; Thomas H Kawula
Journal:  J Bacteriol       Date:  2012-01-20       Impact factor: 3.490

9.  Inhibitors of Ribosome Rescue Arrest Growth of Francisella tularensis at All Stages of Intracellular Replication.

Authors:  Tyler D P Goralski; Kalyan K Dewan; John N Alumasa; Victoria Avanzato; David E Place; Rachel L Markley; Bhuvana Katkere; Seham M Rabadi; Chandra Shekhar Bakshi; Kenneth C Keiler; Girish S Kirimanjeswara
Journal:  Antimicrob Agents Chemother       Date:  2016-05-23       Impact factor: 5.191

10.  Effective, broad spectrum control of virulent bacterial infections using cationic DNA liposome complexes combined with bacterial antigens.

Authors:  Robin Ireland; Norma Olivares-Zavaleta; Jonathan M Warawa; Frank C Gherardini; Clayton Jarrett; B Joseph Hinnebusch; John T Belisle; Jeffery Fairman; Catharine M Bosio
Journal:  PLoS Pathog       Date:  2010-05-27       Impact factor: 6.823

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.